Changes in the Management Board of Eppendorf AG
News Nov 01, 2016
A partial rearranging of the responsibilities in the Management Board of Eppendorf AG will be taking effect in a move designed to further drive the successful implementation of the company's strategy. This includes the creation of a new Board position which will include Sales, Marketing and Service in order to focus on developing the market presence of Eppendorf.
As a result of these changes, the Supervisory Board of Eppendorf AG and Dr. Ralf Hermann, Board member, Chief Marketing & Portfolio Officer, have agreed that the Board mandate shall end by the end of October 2016. The Supervisory Board and the Management Board would like to thank Dr. Hermann for his many years of valuable and dedicated work and wish him all the best for the future.
An FDA-approved drug has been identified that, when used with surgery, hampers metastasis in an animal model. Originally developed and approved ~65 years ago to control blood pressure, the medication resperine also prevents what are known as tumor-derived extracellular vesicles from fusing to healthy cells and sharing their cargo of disease-promoting molecules.READ MORE